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P7C3-A20 neuroprotection is independent of Wallerian
degeneration in primary neuronal culture
Ciaran S. Hilla,b, David K. Menonb,c and Michael P. Colemana
The antiapoptotic, neuroprotective compound P7C3-A20
reduces neurological deficits when administered to murine
in-vivo models of traumatic brain injury. P7C3-A20 is
thought to exert its activity through small-molecule
activation of the enzyme nicotinamide
phosphoribosyltransferase. This enzyme converts
nicotinamide to nicotinamide mononucleotide, the
precursor to nicotinamide adenine dinucleotide synthesis.
Alterations to this bioenergetic pathway have been shown
to induce Wallerian degeneration (WD) of the distal neurite
following injury. This study aimed to establish whether
P7C3-A20, through induction of nicotinamide
phosphoribosyltransferase activity, would affect the rate of
WD. The model systems used were dissociated primary
cortical neurons, dissociated superior cervical ganglion
neurons and superior cervical ganglion explants. P7C3-A20
failed to show any protection against WD induced by neurite
transection or vincristine administration. Furthermore, there
was a concentration-dependent neurotoxicity. These
findings are important in understanding the mechanism by
which P7C3-A20 mediates its effects – a key step before
moving to human clinical trials. NeuroReport 29:1544–1549
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Introduction
In 2010 the antiapoptotic, neuroprotective aminopropyl car-
bazole agent P7C3 was discovered using a novel in-vivo
screening approach [1]. It has been proposed that the com-
pound exerts its actions by activating the enzyme nicotina-
mide phosphoribosyltransferase (NAMPT). NAMPT is the
rate-limiting enzyme in the nicotinamide adenine dinucleo-
tide (NAD) salvage pathway that converts nicotinamide to
nicotinamide mononucleotide (NMN), the precursor to
NAD synthesis (Fig. 1). The NAD salvage pathway is
important in Wallerian degeneration (WD), the active
degeneration of an axon or neurite distal to a site of injury.
P7C3, and one of its more active fluorinated enantiomers
P7C3-A20, has shown promise as a therapeutic agent in a
number of conditions that have been associated with WD.
It was capable of blocking 1-methyl-4phenyl-1,2,3,4-tetra-
hydropyridine-induced death of dopaminergic substantia
nigra cells in an adult mouse model of Parkinson’s disease
[2]. Its ability to protect spinal motor neurons from cell death
was demonstrated both histologically and functionally in the
G93A-SOD1 mouse model of amyotrophic lateral sclerosis
[3]. The potential for benefit of P7C3 derivatives in trau-
matic brain injury (TBI) was indicated by the findings that
the analogue P7C3-S243, prevented retinal ganglion cell
loss following experimental blast injury in mice [4]. This
was followed by a demonstration that P7C3-S243 also
ameliorated behavioural deficits, including motor, learning,
memory loss and axon loss in the CA1 stratum radiatum
region of blast injury exposed mice [5]. Furthermore,
P7C3-A20 administration in a rat fluid-percussion injury
model showed a reduction in contusion volume and
improved sensorimotor and cognitive function [6].
The in-vivo phenotypic screening method by which the
P7C3 compounds were discovered meant that further
work has been required to elucidate their mode of action.
Subsequent research has shown that P7C3-related com-
pounds have some NAMPT-activating activity. NAMPT
is an important enzyme in the WD pathway. However,
the ability of NAMPT activation to protect against WD is
not established and it has not been definitively shown
that NAMPT activation is the means by which
P7C3-based compounds exert their therapeutic action, or
that they do not have other actions.
Materials and methods
Mouse origin and cell culture
C57BL/6 wild-type and SARM1− /− mice were obtained
from Babraham Institute (Babraham, UK). C57BL/
6OlaHsd-Wlds (Wlds) mice, originally obtained from
Harlan (Bicester, UK), were maintained as a separate
colony at the Babraham Institute for 13 years. All animal
work was performed in accordance with the 1986 Animals
(Scientific Procedures) Act under project licence PPL
70/7620. All superior cervical ganglion explant (SCGe)
and dissociated superior cervical ganglion (dSCG)
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cultures were obtained from humanely killed postnatal
day 0 (P0) to P2 mice and were prepared as described
previously [7,8]. Cells were cultured for 7 days in vitro
before experimentation. SCGe were plated on 35 mm
Nunc cell culture dishes (Thermo-Fisher Scientific,
Waltham, Massachusetts, USA), and dSCGs were plated
on low 35mm μ-dishes (ibidi, Martinsried, Germany).
Primary cortical neuronal cells were extracted by dis-
secting out a section of cortical mantle, trypsinizing and
dissociating the neurons before separating by cen-
trifugation. Viability was confirmed to be greater than
95%. The cells were then plated and cultured on low
35mm μ-dishes (ibidi) for 7 days in vitro before experi-
mentation. In all cases, dishes were coated with poly-
L-lysine (25 μg/ml; Sigma, St. Louis, Missouri, USA),
then laminin (2 μg/cm2; Sigma). All cultures were main-
tained in an incubator at a constant 37°C with 5% CO2.
P7C3-A20
The compound P7C3-A20 (cat no. 2850) was sourced
from Cambridge Bioscience (Cambridge, UK) and sup-
plied by Biovision (Milpitas, California, USA) and pre-
pared and used according to manufacturer’s instructions.
Transection and imaging
Transection injury of SCGes was undertaken by a single
linear incision made 2mm from the cell mass with a #10
blade scalpel (Swann-Morton, Sheffield, UK). All images
of SCG and primary cortical neuron (PCN) cultures were
taken on an Olympus IX81 inverted microscope system
(Olympus, Shinjuku, Tokyo, Japan) using × 20 magnifi-
cation and phase-contrast imaging.
Neurite degeneration index
The neurite degeneration index (NDI) is an established
quantitative measure of neurite degeneration (ND) [9].
Images of the same, or similar, the field of neurites are
obtained at different time points or treatment conditions
at a controlled level of magnification (×20) and illumi-
nation. In the case of SCGe the imaged field is typically
5 mm from the main explant mass where the density of
the neurites allows clear visualization of morphological
change. The NDI is calculated by an Image J (University
of Wisconsin, Wisconsin, USA) plug-in algorithm that is
operator independent. The output is a unitless number
from 0 to 1 based on the degree of neurite continuity or
fragmentation. Most healthy neurites score around
0.1–0.3, whereas a profoundly degenerated field would
be in the range of 0.6–0.9. In the case of complete
degeneration, with or without detachment, a score of
0.9 is assigned [9].
NAD/NADH-Glo assay
Levels of NAD were measured using the NAD/NADH-
Glo assay (Promega, Madison, Wisconsin, USA). The
assay was performed according to the manufacturer’s
protocol. The assay contains a cycling reductase enzyme
that reduces a proluciferin reductase substrate to luciferin
in the presence of NADH. Luminescence signals were
measured by PHERAstar plate reader (BMG Labtech,
Ortenberg, Germany).
Statistics
Data are expressed as a mean value with error bars
representing SEM unless otherwise stated. A number of
repeats and replicates and statistical tests are detailed in
each figure legend. A P value of 0.05 or less was con-
sidered significant for any data set. Asterisks represent
the statistical significance as follows: *P≤ 0.05,
**P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001, P< 0.05 (NS).
All statistical tests and graphs were generated with
GraphPad Prism Software, version 7.0 (GraphPad
Software Inc., La Jolla, USA).
Results
To select an appropriate concentration of P7C3-A20 to test
in WD, we first assessed for toxicity over a wide con-
centration range (50 nm to 10 μM) in a variety of neuronal
cell types (Fig. 2). P7C3-A20 induces spontaneous ND, as
measured by the NDI [6], in a concentration-dependent
manner in murine SCGe, SCGd and PCN cultures but
concentrations of 100 nM or below were found to cause no
toxicity at the 24-h timepoint. The ND at concentrations
above 100 nM might follow a Wallerian-like mechanism
following activation of NAMPT leading to overproduction
of NMN. To test this possibility, we asked whether SCGe
cultures from SARM1− /− and Wlds mice showed any less
Fig. 1
The nicotinamide adenine dinucleotide (NAD) synthesis pathway. The
de novo NAD synthesis pathway generates NAD from the essential
aromatic amino acid tryptophan. Nicotinic acid mononucleotide (NaMN)
is converted to nicotinic acid adenine dinucleotide (NaAD) by
nicotinamide mononucleotide adenylyltransferase (NMNAT). NaAD is
then converted to NAD by NAD synthetase. There are three additional
thee salvage pathways. Nicotinamide mononucleotide (NMN) is
produced by nicotinamide phosphoribosyltransferase (NAMPT) from
nicotinamide (NAM), and by nicotinamide riboside kinase (NRK) from
nicotinamide riboside (NR). NMN is then converted to NAD by NMNAT.
Alternatively, NAM is converted to nicotinic acid (NA) by nicotinamidase,
and then NA is converted to NaMN by nicotinic acid
phosphoribosyltransferase (NaPRT). P7C3-A20 is reported to acts as a
small-molecule activator of the enzyme NAMPT within the bioenergetic
NAD synthesis pathway.
P7C3-A20 and Wallerian degeneration Hill et al. 1545
ND at a 10 μM concentration of P7C3-A20, a concentration
that we demonstrated induced ND within 6 h (Fig. 3). In
both SARM1− /− and Wlds cultures, the degeneration was
rapid and comparable to wild-type cultures. This suggests
the mechanism of degeneration at high concentrations of
P7C3-A20 is independent of the WD pathway.
We then tested whether 100 nM P7C3-A20 was able to
rescue NAD depletion caused by doxorubicin in these
neuronal types, as was previously reported for human bone
osteosarcoma epithelial (U2OS) cells [10] (Fig. 4).
Doxorubicin-treated PCN and SCGe cultures showed a
reduction in NAD levels as measured by a luciferin based
(NAD+NADH) assay. This was from an average of 395 485
to 131 406 relative light units in PCN (66.8% reduction,
P≤0.001), and 590892 to 170363 relative light units in SCGe
(71.2% reduction, P<0.01). When doxorubicin-exposed cells
were co-treated with P7C3-A20, there was a partial rescue in
NAD levels in PCN cultures with an average output of
263 886 relative light units; a 34.4% greater maintenance of
NAD levels than seen in untreated cultures (P≤0.001).
However, P7C3-A20 did not rescue the NAD level in SCGs
treated with doxorubicin; these had an average output of
200 318 relative light units. This was not significantly dif-
ferent than the average 170 363 light units seen in SCGs
treated with doxorubicin alone. While we cannot rule out loss
or degradation of NAD from doxorubicin-treated SCGs, this
failure to rescue the NAD levels in SCGs suggests the ability
of P7C3-A20 to activate NAMPT may not be conserved
across all neuronal cell types.
Neurite transection of untreated wild-type SCGe cul-
tures resulted in a progressively increased ND at 6 h –
with a precut degeneration index average of 0.70 and a
6 h post cut index of 0.67 (P≤ 0.0001) (Fig. 5). When
pretreated with P7C3-A20 2 h before transection, or
immediately before the transection, there was no sig-
nificant difference in the degree of WD between the
untreated and treated cultures (average of 0.70 for pre-
treated and 0.76 for those treated at time of cut), hence
indicating that the reported neuroprotective effects of
P7C3-A20 are unlikely to be mediated by a delay in WD.
In dispersed PCN cultures, neurite length and growth pat-
terns make their physical transection unreliable, so
Wallerian-like degeneration was induced with a 100-nM
concentration of vincristine (Fig. 6). Baseline ND scores in
untreated control PCN were an average of 0.3. Six hours
Fig. 2
P7C3-A20 triggers concentration-dependent spontaneous neurite degeneration in a variety of primary neuronal cell types. Neurite degeneration (ND)
was induced in response to various concentrations of P7C3-A20 for 24 h in (a) dissociated superior cervical ganglion cells, (b) superior cervical
ganglion explant and (c) primary cortical neuron cell cultures, in a range of concentrations. Neurite degeneration index was calculated at the time of
treatment and at 24 h afterward. ND shows a concentration-dependent increase with P7C3-A20 administration across all neuronal cell types. The
treatment concentration for subsequent experiments was determined as the maximum concentration at which ND did not occur within this timeframe
(100 nΜ in all cell types). n=12 independent repeats per condition. **P≤0.01, ***P≤0.001, ****P≤0.0001. Error bars show SEM. Statistics: one-
way analysis of variance.
Fig. 3
Removal of SARM1 or expression of Wlds in primary cortical neuron
(PCN) and superior cervical ganglion explant (SCGe) cultures did not
protect against neurite degeneration induced by P7C3-A20. PCNs and
SCGe cultured from wild-type, transgenic SARM1− /−, and WLDs mice
were treated with 10 μM of P7C3-A20 and neurite degeneration
measured 6 h later. In all conditions, there was complete neurite
degeneration and subsequent detachment of the cells. n=9
independent repeats. ****P≤0.0001. Error bars show SEM. Statistics:
Student’s t-test.
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Fig. 4
Doxorubicin induces nicotinamide adenine dinucleotide (NAD) depletion, which is rescued by P7C3-A20 in primary cortical neuron (PCN) cultures
but not in superior cervical ganglion explant (SCGe). (a) PCNs were treated with either DMSO (as control), 100 nΜ of P7C3-A20, 500 nM of
doxorubicin, or a combination of 100 nΜ P7C3-A20 and 500 nM doxorubicin, and incubated for 48 h. The NAD levels were then analysed using a
NAD/NADH-Glo luciferin-based assay (Promega). Luminescence signals were measured and quantified by a PHERAstar plate reader. Doxorubicin
depleted NAD levels in the PCNs and this was partially rescued by P7C3-A20. (b) The experiment was repeated with an SCGe culture but no
significant rescue of NAD levels was seen. n=9 independent repeats. *P≤0.05, **P≤0.01, ***P≤0.001. Error bars show SEM. Statistics: one-way
analysis of variance.
Fig. 5
P7C3-A20 failed to delay Wallerian degeneration in superior cervical ganglion explant (SCGe) following transection. (a) The SCGes were 5-7 DIV,
and either pretreated with P7C3-A20 1 h before cut or at the time of cut. DMSO was used as a control at the time of cut. There was a comparable
degree of degeneration in all conditions at a 6 h timepoint. (b) Representative images of the SCGe cultures are shown at the time of cut and 6 h later
for the control and the P7C3-A20 treated condition. n=8 independent repeats. ****P≤0.0001. Error bars show SEM. Statistics: Student’s t-test.
Fig. 6
P7C3-A20 treatment did not prevent vincristine-induced Wallerian degeneration in primary cortical neuron (PCN) cells. (a) Dissociated primary
neuronal cortical cells were treated with DMSO (as control), 10 nM of vincristine, or 10 nM of vincristine and 100 nΜ of P7C3-A20. The addition of
P7C3-A20 failed to prevent vincristine-induced Wallerian degeneration. (b) Representative images of the PCN cultures are shown at the time of
vincristine treatment and 6 h later for the control and the P7C3-A20 co-treated condition. n=8 independent repeats.****P≤0.0001. Error bars show
SEM. Statistics: Student’s t-test.
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after treatment with vincristine these rose to 0.78
(P≤0.0001). Unlike Wlds and knockout of SARM1 [11,12],
co-treatment of cultures with P7C3-A20 in addition to vin-
cristine did not prevent ND with an average NDI of 0.82.
Discussion
The drug P7C3-A20 has shown promise in various animal
models of neurological disease, including TBI [6],
chronic visual deficits [4], Parkinson’s disease [2] and
amyotrophic lateral sclerosis [13]. It has also been sug-
gested as a possible therapeutic agent for other neuro-
degenerative diseases including Alzheimer’s disease, and
as a preserver of cognitive capacity in aging [1,13].
P7C3-A20 has been shown to enhance neuron formation
in the subgranular zone of the dentate gyrus of adult
mice and protected against apoptotic loss of newborn
hippocampal neurons in neuronal PAS domain protein 3
knockout mice [1].
The in-vivo phenotypic screen by which the P7C3 com-
pounds were discovered meant that further work was
required to elucidate their mode of action. This involved
triggering the death of human osteosarcoma (U2OS) cells
using eight toxic compounds and testing whether P7C3
could rescue any of these. In this way, doxorubicin toxicity
was found to cause P7C3 sensitive cell death. Doxorubicin
is a commonly used chemotherapeutic agent that acts
through a mechanism involving intracellular depletion of
NAD. NAD was partially restored in a concentration-
dependent manner by U2OS cell treatment with P7C3
enantiomers. A photocrosslinking approach followed by
click chemistry with Alexa 532 dye then showed that P7C3
bound to NAMPT. These findings suggested that P7C3
activity might be related to NAMPT activation and related
NAD preservation. This theory is particularly intriguing as
NAMPT and NAD are key molecular players in WD, the
process by which an axon or neurite degenerates distal to a
site of injury. The active degeneration of WD occurs in
both central and peripheral neurons, including PCNs, and
may be an important component of several pathological
entities including many neurodegenerative disorders,
neuropathies and TBI [14]. WD is now recognized as an
active cell-autonomous death pathway.
To progress from animal models to human trials, it is
important to have a thorough understanding of the
mechanistic effects of a drug. This study was undertaken
to further characterize the mechanism of P7C3-A20 action
and to explore the proposition that its effects are because of
NAMPT activation leading to protection against WD.
Several key steps in the WD pathway have been identified
including loss of the enzyme nicotinamide mononucleotide
adenylyltransferase 2 (NMNAT2), for example, in distal
neurites because of interrupted delivery from the soma
following transection injury or transport block [15,16].
Ordinarily, NMNAT2 is produced in the cell soma and
shuttled by kinesin-mediated axonal transport to distal
neurites. Lack of NMNAT2 results in an inability to
convert NMN to NAD. This leads to a rise in NMN and
fall in NAD levels in the distal axon, and is then followed
by a step dependent on sterile-alpha and TIR motif con-
taining protein 1 (SARM1) molecule and subsequent
calcium-mediated axonal fragmentation [17]. SARM1 is a
Toll-like receptor adaptor protein that is a major player in
WD when it is knocked out there the result is delayed
WD. A related spontaneous slow-WD mutation ‘Wlds’
phenotype exists where animals have a long-acting
NMNAT2 like protein ‘WLDs’ that can substitute for
lost NMNAT2 and delay the active WD process. Another
important enzyme in the WD pathways is NAMPT. The
role of NAMPT in WD can be demonstrated through the
use of the NAMPT inhibitor FK866; this blocks the con-
version of nicotinamide to NMN. When murine SCGe
neurons were pretreated with FK866 up to a day before, or
up to 3 h after, transection injury, they showed a delayed
WD phenotype for 24–48 h. However, after 96 h even
uninjured neurites spontaneously degenerated [9]. The
initial delay in WD may have been due to a reduction in
NMN accumulation as the addition of exogenous NMN
could revert protection by FK866. Their eventual degen-
eration may be caused by NAD depletion and cellular
energetic failure.
P7C3-A20 has previously been shown to increase NAD
levels in U2OS cells; following this, we found it was able
to increase NAD levels in selected primary neuronal cell
types. Furthermore, no protection against WD was found
in any cell type, regardless of whether the injury was
physical transection or by vincristine. Vincristine is a
chemotherapeutic drug that causes a length-dependent
axon degeneration [18]. This degeneration is blocked by
Wlds or removal of SARM1 [1,11,19]. Hence, vincristine
is an example of an exogenous chemical agent that can be
used to trigger Wallerian-like degeneration without the
requirement for a physical injury.
The ability of NAMPT to catalyze the metabolism of
nicotinamide to NMN raises intriguing questions about
how P7C3 may influence WD. As long as NMNAT2 is
present in the axon, it will use NMN to synthesize NAD,
but after axon injury, NMNAT2 is rapidly degraded [10,
11] and NMN accumulates [6]. Increasing NAMPT
activity after cutting axons would be expected to lead to
faster accumulation of NMN and thus might increase the
rate of degeneration. In studies where NAMPT expression
was instead reported to be protective, its expression was
increased before axons were cut [20]. The ability of
NAMPT inhibition to delay WD contrasts with the pro-
posed action of P7C3-A20 to block cell death mechanisms
through augmenting NAMPT activity. To resolve this, we
tested the effect of P7C3-A20 on the survival of both
injured and intact axons. We found that P7C3-A20 was
unable to prevent doxorubicin-induced death or to delay
WD in either primary neuronal culture or superior cervical
ganglion cell cultures. Therefore, any therapeutic benefits
1548 NeuroReport 2018, Vol 29 No 18
of the compound may act through different mechanistic
pathways.
Our findings did not support a proposed mechanism of
P7C3-A20 as a NAMPT activator leading to protection
against WD. This suggested that P7C3-A20’s mechanism
of action needs further investigation. Its failure to protect
against WD suggests that it might not be an appropriate
agent to treat diseases that have a large WD-like com-
ponent, for example, chronic inflammatory peripheral
neuropathy, glaucoma and some forms of hereditary
motor sensory neuropathy.
A further finding was the concentration-related toxicity of
P7C3-A20. It has previously been reported in rodent
models to have a wide-therapeutic index [10]. In our
study, we found that there was a marked concentration-
dependent toxicity in all primary neuronal cultures. The
failure of Wlds and SARM1 knockout transgenics to
protect against this suggests that it is due to a mechanism
independent of WD. This toxicity needs to be better
understood, both in its mechanism, in an in-vitro setting
and in the design of any human clinical trials.
Conclusion
The antiapoptotic, neuroprotective agent P7C3-A20
caused ND at concentrations of 500 nM or greater in
dSCG, SCGe and PCN. At concentrations of 100 nM,
P7C3-A20 was able to partially rescue doxorubicin-
induced NAD depletion in PCN, but not in SCGe.
P7C3-A20 failed to delay WD induced by transection
in SCGe, or by vincristine in dissociated PCN. These
findings are significant in understanding the con-
sequences of exposing neurons to various concentrations
of P7C3-A20 and identifying the mechanisms by which
the compound exerts its action. Additional investigation
of the mechanistic action of P7C3-A20 is required to
build the necessary foundation for potential human
studies.
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